Table 2.
CD4 counts (cells/μL) at inclusion and during follow-up for patients with complete follow-up and no malaria reinfection
| Group | Malaria | No malaria | ||||
|---|---|---|---|---|---|---|
| HIV infected (N = 67) | HIV uninfected (N = 51) | HIV infected (N = 59) | ||||
| CD4 counts | Median (IQR) | P | Median (IQR) | P | Median (IQR) | P |
| Day 0 | 364 (242–483) | – | 563 (450–903) | – | 382 (243–538) | – |
| N = 66 | N = 43 | N = 49 | ||||
| Day 7 | 453 (359–625) | < 0.001 | 875 (713–1,021) | < 0.001 | 399 (247–546) | NS |
| N = 57 | N = 26 | N = 46 | ||||
| Day 42 | 482 (302–636) | < 0.001 | 888 (727–1,069) | < 0.001 | 418 (254–540) | NS |
| N = 66 | N = 48 | N = 49 | ||||
HIV = human immunodeficiency virus; IQR = interquartile range; NS = not significant.
Changes from enrollment levels were assessed with Wilcoxon signed-rank test. CD4-counts were unavailable in a period of the study, resulting in a lack of CD4 count for some patients. At inclusion (day 0) CD4 counts were higher in the HIV-uninfected group compared with the HIV-infected groups (P < 0.001 for both HIV-infected groups). The CD4 counts were comparable for the HIV-infected groups at inclusion (P = 0.73).